Tackling these resistance mechanisms may require combination approaches, such as pairing PARP inhibitors with ATR or WEE1 inhibitors to prevent replication stress recovery, or with checkpoint inhibitors to enhance tumor immunogenicity (57, 58). This evidence concerns the gene PARP1 and neoplasm.